泽璟制药-U
(688266)
| 流通市值：318.05亿 | | | 总市值：318.05亿 |
| 流通股本：2.65亿 | | | 总股本：2.65亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 1,205,379,571.43 | 905,391,322.84 | 810,484,651.18 | 593,440,129.02 |
| 营业总成本 | 582,362,043.04 | 272,317,383.64 | 1,025,913,989.8 | 720,231,851.57 |
| 其他经营收益 | | | | |
| 营业利润 | 638,662,061.99 | 632,287,204.83 | -168,013,241.88 | -96,762,629.52 |
| 利润总额 | 638,646,561.5 | 631,770,599.4 | -168,654,782.77 | -98,319,633.96 |
| 净利润 | 640,011,104.13 | 632,612,572.5 | -165,126,809.51 | -95,596,820.94 |
| 每股收益 | | | | |
| 其他综合收益 | 27,083.85 | -6,314.96 | 366,110.72 | -598,227.97 |
| 综合收益总额 | 640,038,187.98 | 632,606,257.54 | -164,760,698.79 | -96,195,048.91 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 2,961,968,779.76 | 3,158,916,488.27 | 2,443,104,161.9 | 2,505,923,345.63 |
| 非流动资产: | | | | |
| 非流动资产合计 | 564,271,369.49 | 529,469,658.6 | 526,081,429 | 507,454,092.73 |
| 资产总计 | 3,526,240,149.25 | 3,688,386,146.87 | 2,969,185,590.9 | 3,013,377,438.36 |
| 流动负债: | | | | |
| 流动负债合计 | 1,185,164,883.95 | 1,338,521,484.91 | 1,427,939,874.32 | 1,354,855,501.35 |
| 非流动负债: | | | | |
| 非流动负债合计 | 620,588,851.32 | 636,810,178.42 | 460,797,490.58 | 509,508,061.13 |
| 负债合计 | 1,805,753,735.27 | 1,975,331,663.33 | 1,888,737,364.9 | 1,864,363,562.48 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 1,720,486,413.98 | 1,713,054,483.54 | 1,080,448,226 | 1,149,013,875.88 |
| 股东权益合计 | 1,720,486,413.98 | 1,713,054,483.54 | 1,080,448,226 | 1,149,013,875.88 |
| 负债和股东权益合计 | 3,526,240,149.25 | 3,688,386,146.87 | 2,969,185,590.9 | 3,013,377,438.36 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 1,491,530,336.17 | 1,144,731,089.33 | 1,055,481,598.12 | 766,141,565.65 |
| 经营活动现金流出小计 | 683,016,423.05 | 307,316,593.21 | 1,084,263,584.36 | 782,875,487.51 |
| 经营活动产生的现金流量净额 | 808,513,913.12 | 837,414,496.12 | -28,781,986.24 | -16,733,921.86 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 2,016,309,138.91 | 428,238,736.11 | 125,832,291.34 | 65,943,533.33 |
| 投资活动现金流出小计 | 1,603,871,146.62 | 1,033,253,949.86 | 181,466,703.44 | 132,497,229.06 |
| 投资活动产生的现金流量净额 | 412,437,992.29 | -605,015,213.75 | -55,634,412.1 | -66,553,695.73 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 56,000,000 | 56,000,000 | 1,126,882,468.69 | 616,021,145.08 |
| 筹资活动现金流出小计 | 393,629,955.69 | 213,981,663.74 | 1,134,383,480.86 | 616,706,142 |
| 筹资活动产生的现金流量净额 | -337,629,955.69 | -157,981,663.74 | -7,501,012.17 | -684,996.92 |
| 汇率变动对现金及现金等价物的影响 | -5,348,578.27 | -4,503,785.11 | -690,409.18 | -527,602.39 |
| 现金及现金等价物净增加额 | 877,973,371.45 | 69,913,833.52 | -92,607,819.69 | -84,500,216.9 |
| 期末现金及现金等价物余额 | 1,002,631,044.84 | 194,571,506.91 | 124,657,673.39 | 132,765,276.18 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | 877,973,371.45 | - | -92,607,819.69 | - |
最新报告期：2026-08-24| 研究机构 | 分析师 | 预测每股收益(元) | 更新日 |
| 2026年 | 2027年 | 2028年 |
| 广发证券 | 罗佳荣 | 2.19 | 1.44 | 2.33 | 2026-08-24 |
| 华泰证券 | 代雯,李奕玮 | 2.04 | 1.80 | 1.05 | 2026-08-20 |
| 中信建投 | 沈毅,赵旭,袁清慧,贺菊颖 | 2.82 | 0.26 | 1.10 | 2026-08-18 |
| 浙商证券 | 盖文化,郭双喜 | 1.93 | 1.61 | 2.17 | 2026-08-16 |
| 中信建投 | 沈毅,赵旭,袁清慧,贺菊颖 | 2.82 | 0.26 | 1.10 | 2026-08-11 |